Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 12 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Canagliflozin-Mealtime Insulin RescueStatus unknownNCT02624908Phase 4
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes PatientsCompletedNCT02616666Phase 4
- Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to GliclazideCompletedNCT02610088Phase 4
- The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 InsulinWithdrawnNCT02597309Phase 4
- Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial EffectsCompletedNCT02585804Phase 4
- Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)Status unknownNCT02577159Phase 4
- Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy MetabolismStatus unknownNCT02558270Phase 2
- Tofogliflozin GLP-1 Analogue Combination TrialCompletedNCT02537834Phase 4
- Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusCompletedNCT02529449Phase 2
- Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) InhibitorsStatus unknownNCT02528019Phase 4
- Effect of Dapagliflozine on Systemic and Renal Endothelial FunctionStatus unknownNCT02501616Phase 4
- The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) InhibitorCompletedNCT02500186Not applicable
- Oral Contraceptive DDI StudyStatus unknownNCT02494609Phase 1
- Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium FunctionCompletedNCT02471963Phase 3
- PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentCompletedNCT02471274Phase 1
- Effect of Dapagliflozin on Glycemic VariabilityCompletedNCT02459353Phase 4
- A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02452632Phase 3
- Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta CellCompletedNCT02420392Not applicable
- Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy VolunteersCompletedNCT02404870Phase 1
- Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and DiabetesCompletedNCT02397421Phase 4
- Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium ContentCompletedNCT02383238Phase 3
- Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsCompletedNCT02373046Phase 1
- Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 DiabetesStatus unknownNCT02372955Phase 4
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
- The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic PatientsCompletedNCT02327039Phase 4
- Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 DiabetesCompletedNCT02325206Phase 1
- Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body WeightCompletedNCT02313220Phase 2
- DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinCompletedNCT02300363Phase 1
- Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02291874Phase 4
- Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersCompletedNCT02276365Phase 1
- Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseCompletedNCT02253121Phase 4
- Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02221180Phase 1
- Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted ParticipantsCompletedNCT02220218Phase 1
- Dapagliflozin in Type 1 DiabetesCompletedNCT02211742Phase 4
- Single Rising Oral Doses of BI 10773 in Healthy Male VolunteersCompletedNCT02182453Phase 1
- A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes MellitusCompletedNCT02175784Phase 4
- BI 10773 Administered as Oral Solution to Healthy Male VolunteersCompletedNCT02172274Phase 1
- Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersCompletedNCT02172261Phase 1
- Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersCompletedNCT02172248Phase 1
- Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy VolunteersCompletedNCT02172235Phase 1
- Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
- Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male VolunteersCompletedNCT02172209Phase 1
- Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male SubjectsCompletedNCT02172170Phase 1
- Glycemic Durability After Metformin FailureStatus unknownNCT02142309Phase 4
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsCompletedNCT02077803Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual ComponentsCompletedNCT02073227Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsCompletedNCT02071368Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual ComponentsCompletedNCT02065752Phase 1
- Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
- Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical TreatmentCompletedNCT02041234Phase 4
- Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02009488Phase 1
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes MellitusCompletedNCT02000700Phase 1
- Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 DiabetesWithdrawnNCT01984606Phase 3
- A Study to Compare the Oral Absorption of ASP1941 Among Two Types of TabletsCompletedNCT01972880Phase 1
- Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCompletedNCT01916863Phase 1
- Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsCompletedNCT01916850Phase 1
- Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsCompletedNCT01913002Phase 1
- A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy VolunteersCompletedNCT01877889Phase 1
- Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With DiabetesWithdrawnNCT01824264Phase 2
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy VolunteersCompletedNCT01821027Phase 1
- Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsCompletedNCT01818232Phase 1
- A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)CompletedNCT01787357Phase 1
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney FunctionCompletedNCT01759576Phase 1
- A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy VolunteersCompletedNCT01756417Phase 1
- Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese VolunteersCompletedNCT01756404Phase 1
- A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian VolunteersCompletedNCT01748526Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy VolunteersCompletedNCT01733108Phase 1
- A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy VolunteersCompletedNCT01718652Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.CompletedNCT01714206Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy VolunteersCompletedNCT01714193Phase 1
- A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese VolunteersCompletedNCT01707316Phase 1
- Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy AdultsCompletedNCT01678287Phase 1
- A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941CompletedNCT01674777Phase 1
- A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes PatientsCompletedNCT01672762Phase 3
- Effects of Canagliflozin on C-peptide Clearance in Healthy VolunteersCompletedNCT01665638Phase 1
- Absolute Bioavailability Study With IpragliflozinCompletedNCT01611428Phase 1
- Drug to Drug Interaction Study With Ipragliflozin and FurosemideCompletedNCT01611415Phase 1
- A Phase 1 Study to Investigate the Mechanism of Action of IpragliflozinCompletedNCT01611363Phase 1
- A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes MellitusCompletedNCT01571661Phase 1
- Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCompletedNCT01555008Phase 1
- A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusTerminatedNCT01514838Phase 3
- A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy VolunteersCompletedNCT01508195Phase 1
- A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy VolunteersCompletedNCT01508182Phase 1
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes PatientsCompletedNCT01505426Phase 3
- A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes MellitusCompletedNCT01483781Phase 1
- A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersCompletedNCT01463774Phase 1
- A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
- A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy VolunteersCompletedNCT01428284Phase 1
- Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01407003Phase 1/2
- A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma ConcentrationCompletedNCT01403818Phase 1
- A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy VolunteersCompletedNCT01395927Phase 1
- A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes MellitusCompletedNCT01381887Phase 1
- A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese SubjectsCompletedNCT01373060Phase 1
- The Effect of Food on the Administration of Canagliflozin in Healthy Adult VolunteersCompletedNCT01343290Phase 1
- A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy VolunteersCompletedNCT01340677Phase 1
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedNCT01316107Phase 3
- A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentCompletedNCT01316094Phase 3
- Drug-drug Interaction Study With ASP1941 and GlimepirideCompletedNCT01302158Phase 1
- Drug to Drug Interaction Study With ASP1941 and MetforminCompletedNCT01302145Phase 1